



## Specialty pharmacy prior authorization update — drugs for treatment of ocular conditions

**Summary of change:** In a recent provider update, we advised we would no longer require prior authorization (PA) for the following drugs used to treat ocular conditions, effective May 1, 2021. Please be advised that PA will continue to be required for these drugs. We apologize for any inconvenience.

Drug	Code	Code description
*Avastin	J9035	intravitreal bevacizumab
*Mvasi	Q5107	bevacizumab-awwb
*Zirabev	Q5118	bevacizumab-bvzr

\* Our specialty drug review team manages non-oncology use.

<https://providers.amerigroup.com/TX>